NSF Awards U.S. Genomics a $500K Phase II-B SBIR Grant
News Oct 07, 2005
U.S. Genomics, Inc. has announced that it has received a Phase II-B SBIR grant from the National Science Foundation.
The $500,000 grant is earmarked for development of a commercial platform that uses the Company's rapid DNA analysis and genomic mapping technologies.
U.S. Genomics plans to use this installment to develop its Substance Identification and Quantitation Using Molecular Barcodes (SIQUMB) technology.
“This additional SBIR award recognizes the achievements we've made in developing single molecule analysis and genomic mapping for commercialization,” said John J. Canepa, acting Chief Executive Officer of U.S. Genomics.
“The ability to acquire and analyze molecular information has been made much more efficient with the invention of the SIQUMB molecular identification process.”
“This technology will be valuable for many commercial applications in life science research and in the healthcare industry.”
In July 2002, U.S. Genomics was awarded Phase I of the SBIR grant to create genomic maps by tagging and stretching individual DNA molecules.
During the Phase I project, U.S. Genomics achieved fundamental milestones by mapping long DNA molecules and substantially increasing the throughput and accuracy of the mapping technology.
In August 2003, the Company earned the subsequent Phase II grant. As part of the Phase II application, researchers at U.S. Genomics enhanced the capabilities of the DNA mapping platform and invented SIQUMB.
The recent award will enable U.S. Genomics to continue its development and commercialization of the SIQUMB technology.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018